MD
Medically Reviewed & Fact-Checked
E-E-A-T VerifiedAll clinical answers strictly conform to peer-reviewed regenerative medicine literature and the National Guidelines for Stem Cell Research under ICMR-DBT oversight.
No Matching Questions Found
We could not find an exact match for your query. Our clinical team can directly answer any specific questions regarding your condition or medical reports.
Ask Medical Desk on WhatsApp1. Cellular Biology & Sourcing Protocols
Core regenerative mechanisms, donor ethics, and cell types
Stem cells are primitive, undifferentiated biological master cells capable of continuous self-renewal (replicating themselves) and multilineage differentiation into specialized functional cells such as neural progenitors, cardiomyocytes, chondrocytes, or hepatocyte-like cells. In therapeutic applications, they exert paracrine signaling, secrete neurotrophic factors, stimulate endogenous tissue repair mechanisms, and modulate chronic systemic inflammation.
Yes, 100% ethically sourced under strict institutional oversight. Our partner facilities utilize two verified cell sources:
- Autologous Stem Cells: Harvested directly from the patient's own posterior iliac crest bone marrow or subcutaneous adipose tissue under local anesthesia. Zero risk of graft-versus-host disease (GvHD).
- Allogeneic Mesenchymal Stem Cells (UC-MSCs): Screened from donated human umbilical cord tissue (Wharton's Jelly) following scheduled, healthy full-term cesarean births with informed maternal consent. These cells are immune-privileged (low HLA-DR expression) and require zero immunosuppressive drugs.
No, absolutely not. In accordance with Indian ICMR-DBT guidelines and international medical ethics, our partner institutions never use embryonic or aborted fetal tissue. Embryonic cells carry documented risks of teratoma (tumor) formation and severe immunological rejection. We only administer adult autologous or neonatal umbilical cord tissue mesenchymal stem cells (MSCs), which possess an impeccable clinical safety record.
In compliance with ethical medical disclosure, stem cell therapy should not be represented as a guaranteed "100% cure" for progressive or degenerative medical conditions. The clinical goals of regenerative intervention are:
- Halting or decelerating ongoing degenerative disease progression.
- Repairing and re-vascularizing compromised tissue micro-environments.
- Measurable quality-of-life improvements (motor function, bladder control, speech, energy, pain relief).
- Reducing dependency on high-dose pharmaceuticals or frequent hospitalizations.
Autologous cells come from your own body, ensuring 100% genetic compatibility, but their potency and proliferative vitality may decrease in older patients or patients with chronic metabolic illness. Allogeneic Umbilical Cord MSCs (UC-MSCs) are "day-zero" youthful cells with superior expansion potential, higher paracrine growth factor secretion, and natural immune-evasive properties, making them ideal when rapid cellular yield is essential.
2. Clinical Eligibility & Candidate Screening
Inclusion criteria, treatable diseases, age guidelines, and medical evaluations
Our accredited partner hospitals feature specialized protocols across 66 clinically evaluated indications organized into 5 primary specialties:
Neurological (22 conditions): ALS, Cerebral Palsy, Parkinson's, Stroke, Multiple Sclerosis, Spinal Cord Injury, Ataxia, Autism Spectrum (ASD).
Organ & Metabolic (14 conditions): Chronic Kidney Disease (CKD), Type 1 & 2 Diabetes, Diabetic Neuropathy, Liver Cirrhosis, Erectile Dysfunction.
Orthopedic & Spine (15 conditions): Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis (AVN), Degenerative Disc Disease.
Vision & Eye (6 conditions): Optic Nerve Atrophy (ONA), Glaucoma, Macular Degeneration (AMD), Retinitis Pigmentosa.
Patients with active malignancies cannot receive mesenchymal stem cell therapy because the angiogenic growth factors secreted by regenerative cells could theoretically promote tumor neo-vascularization. However, our specialized oncology partners do offer targeted cellular immunotherapies (such as Autologous Dendritic Cell Therapy and Natural Killer (NK) Cell Infusions) specifically designed to target refractory solid tumors under oncology board protocols.
The screening is free and 100% confidential. You submit recent medical records (discharge summaries, MRI/CT scans, blood panels, and current medications) via our online form or WhatsApp desk. Our multidisciplinary board of neurologists, orthopedic surgeons, and cellular biologists evaluates:
- Stage and severity of disease progression.
- Absence of exclusionary contraindications (active systemic infection, active cancer, severe unmanaged cardiovascular crisis).
- Realistic therapeutic target endpoints and expected degree of functional recovery.
There is no arbitrary chronological age cutoff. We have safely treated pediatric patients as young as 18 months (for Cerebral Palsy, Autism Spectrum Disorder, or global developmental delay) through senior patients up to 88 years of age (for advanced Osteoarthritis, Parkinson's, or Post-Stroke rehab). Dosages and cell quantities are carefully calibrated by kilogram of body weight.
3. Procedure, Administration & Clinical Safety
Infusion delivery routes, side effects, cGMP cleanroom sterility, and hospital stay
Administration routes depend strictly on the target anatomy and condition etiology:
- Intravenous (IV) Infusion: Painless drip over 45 to 60 minutes for systemic organ, autoimmune, anti-ageing, and vascular conditions.
- Intrathecal (Lumbar Puncture): Administered into the cerebrospinal fluid (CSF) by an experienced neuro-anesthesiologist to bypass the blood-brain barrier for brain and spinal cord indications.
- Intra-Articular Injections: Targeted ultrasound-guided delivery directly into knee, shoulder, or hip articular joint spaces.
- Retrobulbar / Peribulbar: Specialized micro-injections around the ocular orbit for optic nerve and retinal indications.
Stem cell therapy exhibits a thoroughly documented, benign clinical safety record. The most common minor and temporary side effects include:
- Mild, transient low-grade fever (37.5°C - 38.2°C) lasting 6 to 18 hours as cytokines activate.
- Mild post-lumbar headache after intrathecal delivery, readily managed with bed rest and oral hydration.
- Localized soreness at the aspiration or injection puncture site that resolves within 24 to 48 hours.
All cell harvesting and processing takes place in ISO Class 10,000 / Class 100 laminar-flow cGMP cleanroom laboratories. Prior to release, each patient batch undergoes automated multi-parameter testing:
- Viability: Confirmed >90% cell viability using automated trypan blue / acridine orange flow cytometry.
- Cell Count: High-yield counts typically exceeding 50 to 150 million live MSCs per treatment protocol.
- Sterility & Safety: Rapid PCR tests for aerobic/anaerobic bacteria, fungal pathogens, mycoplasma, and endotoxin levels (<0.5 EU/mL) compliant with international pharmacopeia.
For international patients, our protocols generally utilize a 3 to 5 day inpatient or day-care hospital stay. This guarantees continuous clinical monitoring, completion of baseline diagnostic imaging, pre-infusion hydration, and integration with daily physical, occupational, and hyperbaric oxygen (HBOT) rehabilitation sessions under one roof.
4. Treatment Costs, Indian Medical Visa & Concierge
Pricing transparency, package inclusions, visa assistance, airport transfers, and follow-up
India is a global powerhouse for pharmaceutical biotechnology and clinical manufacturing. The substantial price difference (e.g. $4,000 - $8,000 USD in India vs. $25,000 - $70,000 USD in the US, Europe, or Mexico) is driven by:
- Domestic manufacture of clinical-grade media and bioprocessing reagents.
- Lower hospital infrastructure overhead and administrative litigation costs.
- Favorable currency exchange rates without compromising on NABH/ISO quality standards.
We provide transparent, fixed-price package quotations with zero hidden charges. Packages typically encompass:
- Pre-treatment laboratory blood testing and diagnostic imaging.
- Stem cell harvesting, cGMP cleanroom processing, and cell administration.
- Hospital private suite accommodation with caregiver sleeper sofa and meals.
- Comprehensive physiotherapy, occupational therapy, and neuro-stimulation.
- Private airport chauffeur pickup and drop-off (DEL, BOM, BLR, MAA).
- Complimentary local SIM card and dedicated international language coordinator.
Our international desk manages the complete visa documentation workflow. Once treatment dates are confirmed, we issue an official Hospital Medical Visa Invitation Letter on hospital letterhead with the treating physician's stamp. You apply online for an Indian e-Medical Visa (and e-Medical Attendant Visa for up to two accompanying family members), typically approved by the Indian Ministry of Home Affairs within 72 to 96 hours.
The standard recommended itinerary is 5 to 7 days in India:
- Day 1: Airport arrival, private transfer to hospital hub, admission, clinical baseline tests.
- Day 2: Harvesting (if autologous) or pre-infusion priming, specialist consultations.
- Day 3: Cleanroom cell administration (IV / Intrathecal / Local) + initial physical therapy.
- Day 4: Post-infusion observation, intensive neuro-rehab, hyperbaric oxygen session.
- Day 5-7: Final physician clearance, discharge summary issuance, return airport transfer.
Our care continuum does not end at discharge. Your dedicated coordinator schedules structured video tele-consultations at 1-month, 3-month, 6-month, and 12-month post-procedure intervals. Our clinical team reviews local blood tests, MRI scans, and functional motor score sheets, collaborating with your hometown physician to optimize long-term rehabilitation.
5. Clinical Outcomes & Neuro-Rehabilitation
Improvement timeline, physical therapy synergy, and repeat booster sessions
Cellular regeneration is a biological process that unfolds gradually:
- Weeks 1 - 4: Reductions in systemic inflammation, diminished spasticity, improved energy, better sleep quality, and reduced localized pain.
- Months 2 - 4: Active cellular homing and paracrine signaling foster new micro-vascularization and synaptic connections. Noticeable improvements in motor coordination, muscle strength, or organ biomarkers.
- Months 4 - 9: Peak clinical improvements typically stabilize as structural tissue remodeling and neuroplastic reorganization solidify.
Stem cells introduce fertile biological repair capacity, but active neuroplastic reorganization requires functional physical signaling. Daily physical therapy, occupational drills, robotic gait training, and hyperbaric oxygen therapy (HBOT) "teach" newly stimulated neural pathways how to operate, multiplying long-term functional recovery compared to cell therapy alone.
Yes. For chronic progressive conditions such as advanced ALS, severe Parkinson's, or end-stage osteoarthritis, a secondary booster protocol scheduled 6 to 12 months after the initial protocol can reinforce tissue stabilization and extend functional gains. Eligibility for repeat treatment is determined via remote follow-up evaluation.
24/7 International Medical Desk
Have a Question Not Listed Here?
Our senior medical counselors and advisory physicians are on standby to review your case history, interpret diagnostics, and outline a tailored regenerative plan.
Confidential Intake
Check Treatment Eligibility
Submit diagnostic summaries for a free medical review within 24 business hours.